Polyendocrine metabolic ovarian syndrome (PMOS)

DBCOND0174253Endocrine System DiseasesUrogenital Diseases

Polyendocrine metabolic ovarian syndrome (PMOS) is the indication for 9 drugs in DrugBank. It is covered by 9 curated, structured indications.

Also known as
Polycystic Ovary Syndrome · PCOS · Polycystic Ovarian Syndrome · Polycystic Ovaries · Polycystic Ovary Syndrome (PCOS)
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0017165ICD-10E28.2SNOMED CT154714009MedDRA10036049UMLSC0032460

What you can answer from here — as of September 29, 2026

9Indicated drugsWith each drug's targets and mechanism
Listed above
9Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
590Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Polyendocrine metabolic ovarian syndrome (PMOS) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In